Notably, lenalidomide inhibits MALT1-mediated BCL10 cleavage (an indicator of CBM complex activation) and suppresses NFκB activity in non-GCB DLBCL cell lines (22). The gene discussed is MALT1; the disease is diffuse large B-cell lymphoma.